Overview
- The FDA’s Pharmacy Compounding Advisory Committee voted on July 23–24 to recommend adding six of seven peptides under review to the Section 503A Bulks List, which governs substances state‑licensed compounding pharmacies may use.
- Patient‑safety groups and career FDA reviewers say the panel advanced the substances despite weak human trial evidence and flagged harms from immune reactions, manufacturing impurities and the risk that growth‑promoting peptides could encourage tumor growth in people with undiagnosed cancer.
- Peptide advocates argue regulated compounding could pull patients away from unregulated online 'research use only' products and stressed the need for validated ingredient testing, pharmacy manufacturing standards, clinician training and patient follow‑up.
- The committee’s recommendation is nonbinding; the FDA will now review the meeting record, public comments and staff analyses and may begin formal rulemaking that would take months to a year and would not make the peptides FDA‑approved drugs.
- The vote has raised public trust questions because some new advisory members have financial links to peptide businesses and because the six peptides were among substances previously restricted in 2023 due to safety concerns, which leaves patients facing tradeoffs between gray‑market access and uncertain regulated availability.